A/Prof Jeremy Grummet, MBBS, MS, FRACS, is a practising academic urologist and Director of Urology at Alfred Health who is expert in prostate cancer diagnosis and treatment. His overarching aim is to provide value-based care for maximal wellbeing.

He has pioneered transperineal biopsy (via the skin) as a safer technique for performing prostate biopsy, avoiding the risks of sepsis associated with the traditional transrectal (via the rectum) technique. Transperineal biopsy is now both the recommended standard of care in official European and Australian clinical guidelines and the most used prostate biopsy technique in Australia. Jeremy is a leader of the global TREXIT movement, aiming to end the practice of transrectal biopsy and train colleagues in the transperineal technique.

He is the co-founder of MRI PRO, a unique globally used online training program whose aim is to improve the accuracy and standards of prostate MRI reporting around the world. MRI PRO is achieving that aim, with over 1,000 users of its prostate MRI cases and its webinar videos being viewed thousands of times by radiologists and urologists from over 90 countries.

Jeremy was the only non-European Member of the European Association of Urology (EAU) Prostate Cancer Guidelines Panel. These Guidelines are used throughout Europe and endorsed globally outside North America, including by the Urological Society of Australia and New Zealand (USANZ).

He is also a Co-Primary Investigator on the LIBERATE and FIREFLY prospective clinical registries of focal therapy for single focus intermediate-risk localised prostate cancer, now recruiting in Australia. Now that accurate imaging is available to determine the precise location of cancer within the prostate, the next logical step is to research highly targeted treatment to minimise the quality of life impacting side effects seen commonly with traditional radical therapies. This organ-sparing approach is already standard of care for other solid organ cancers, such as breast cancer.

Recognising that most of the controversies surrounding prostate cancer start with its diagnosis, A/Prof Grummet has focused his research on prostate cancer diagnostics including MRI and biopsy, and supervises Master of Surgery and Bachelor of Medical Science researchers in this field. Topics under investigation include the risk of biopsy sepsis, diagnostic accuracy, the role of MRI-targeted biopsy, and PSMA PET scanning. He is now taking the research findings in diagnosis into the therapeutic space with clinical registries in focal therapy.

Prostate MRI Training Course

Students will analyse 300 full prostate MRI cases, performed to PIRADS (Prostate Imaging Reporting and Data System) v2.1 standard, online. For each case, students will analyse the MRI and will be required to give their answers in four domains, which are all clinically focused.

Following completion of each case, students submit their answers and are immediately shown the correct answer and where their answer diverges from it for each component. Students are also shown the full histology of the prostate for all cases positive for cancer, as well as annotated MRI images with lesions circled, for immediate feedback.

Students can also return to the MRI images after each case to review where they have got their answer right or wrong.

To progress to the next case, students must submit their answer, ensuring interactive learning. They will also be able to track their own progress and improvement in accuracy using the My Progress feature, showing a detailed breakdown of their strengths and weaknesses in PIRADS scoring of each MRI. Students must successfully complete AT1, AT2 and AT4 for at least 20 consecutive cases with at least 80% accuracy.